On 10 October, at the American Heart Association (AHA) 2025 conference in New Orleans, Louisiana, US, during a late-breaking session on the topic of ‘Lipid Therapies: Translation to Implementation’, Chao Lv presented findings of Jiangsu Henrui Pharmaceuticals, SHR-1918, in patients with suboptimally controlled hyperlipidaemia.
Suboptimally controlled hyperlipidaemia remains a major challenge in cardiovascular care, affecting patients whose cholesterol and lipid levels stay elevated despite treatment with established therapies such as statins, ezetimibe, or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. High levels of low-density lipoprotein cholesterol (LDL-C) and other dangerous lipids are key contributors to life-threatening events such as heart attack and stroke. While current oral and injectable treatments have led to significant progress, many patients are still unable to reach their target lipid levels or experience side effects that limit their options. As a result, there is an urgent demand for innovative solutions – such as therapies directed at angiopoietin-like proteins – to help address the unmet needs of those with persistent, difficult-to-treat hyperlipidaemia.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
SHR-1918 is a fully human monoclonal antibody that specifically targets angiopoietin-like protein 3 (ANGPTL-3), offering a new approach to help patients who continue to have high LDL cholesterol and triglycerides despite standard therapies by safely and effectively lowering these lipids through potent inhibition of ANGPTL-3 activity. The presentation highlighted after 24 weeks, SHR-1918 demonstrated meaningful improvements in key lipid parameters, reducing LDL-C by 20.8% and 25.1% at the 600mg and 1,200 mg doses, respectively, compared with a 2.2% reduction in the placebo group. Triglyceride levels were reduced by 49.8% and 58.8% in the SHR-1918 groups, versus 1.2% with placebo, and significant decreases were also observed in non-high-density lipoprotein cholesterol, total cholesterol, and additional atherogenic lipids. SHR-1918 was generally well tolerated, with mild to moderate treatment-emergent adverse events reported at rates similar to placebo and no discontinuations or deaths.
In conclusion, this pivotal study of SHR-1918 marks a transformative moment in the management of persistent hyperlipidaemia for patients inadequately controlled on current therapies. These results raise expectations for the new lipid-lowering agents. Within this competitive context, SHR-1918’s encouraging efficacy and favourable safety profile position it as an attractive pipeline agent, well suited to occupy an important therapeutic niche between existing oral therapies and established PCSK9-targeting biologics.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
